Pharmafile Logo
Pharmafocus logo
Advanced Search

iOnctura expands clinical trial programme for NSCLC

July 9, 2024
Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

News

Roche gains CE Mark for AI glucose monitoring system for diabetes management

July 9, 2024
Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.

News

Oxolife shares data from phase 2 trial for infertility drug

July 8, 2024
Research and Development Oxolife, Reproductive health, clinical trial, infertility

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …

News

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …

News

GSK and CureVac to restructure collaboration into licensing agreement

July 3, 2024
Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration

GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …

News

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024
Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …

News

Arcturus Therapeutics provides update on OTC deficiency and CF programmes

July 2, 2024
Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis

Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …

News

NeuroSense shares update from ALS treatment trial

July 2, 2024
Research and Development NeuroSense, Neurology, als, clinical trial

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …

News

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024
Research and Development MS, Neurology, Sanofi, multiple sclerosis

Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …

News

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024
Research and Development COVID-19, EMA, Infections and infestations, coronavirus

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024
Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …

News

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024
Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024
Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology

Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …

News
brain_mri_131749_t1

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024
Research and Development MimiVax, Oncology, Orphan Drug Designation, Roswell Park Comprehensive Cancer Center, immunotherapies, oncology

The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, …

News

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024
Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart

Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …

News
max-bender-w5bn80xghre-unsplash_1

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024
Research and Development AskBio, Neurology, Parkinson's disease, clinical trial

Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …

News

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …

News

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024
Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough

ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …

News

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024
Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …

News

Vertex shares results from phase 1/2 trial of type 1 diabetes treatment

June 24, 2024
Research and Development Diabetes, Vertex pharmaceuticals, clinical trial, diabetes

Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025